Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of Atypical Resistant Facial Pain
Sponsor: Alenka Spindler-Vesel
Summary
Facial pain in the trigeminal nerve region, which is not a migraine headache is often very persistent and difficult to treat. Research findings suggest that, similar to the mechanisms of migraine headache, the increased concentration of calcitonin gene-related peptide (CGRP) plays an important role in the mechanisms of facial pain. Therefore, the hypothesis is that intravenous administration of ACMP will similarly disrupt central sensitization in facial pain as it does in migraine headaches.
Official title: The Impact of Intravenous Administration of ACMP (Eptinezumab) on the Treatment of Atypical Resistant Facial Pain
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
10
Start Date
2025-11-03
Completion Date
2026-12-03
Last Updated
2025-12-22
Healthy Volunteers
No
Conditions
Interventions
intravenous administration of ACMP
30-minute infusion of 100 mg of eptinezumab, repeated after three months
Locations (1)
Pain Therapy Clinic of University Medical Centre Ljubljana
Ljubljana, Slovenia